다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
大韓癌韓醫學會誌 = Journal of Korean traditional oncology, v.20 no.1, 2015년, pp.55 - 79
홍상훈 (동의대학교 한의과대학 내과학교실) , 손호영 (바른몸 맑은 한의원)
AI-Helper
Hepatocellular carcinoma(HCC) is the fifth most common cancer worldwide (fifth in male, seventh in female) and the third most common cause of cancer mortality. Since 2001, the various research group in the United States, Europe and Asia have published clinical practice guidelines for HCC. In Korea, ...
| 핵심어 | 질문 | 논문에서 추출한 답변 |
|---|---|---|
| 간세포암종의 발병율은? | 간세포암종(hepatocellular carcinoma)은 간에서 발생하는 암의 80-90%를 차지하는 암이고, 전세계적으로 광범위하게 퍼져 있어서 암 발병율 5위(남성 5위, 여성 7위), 암으로 인한 사망원인으로는 3위를 차지하는 암이다. 간세포암종 (hepatocellular carcinoma)의 남녀 발생 비율은 4:1로 남자가 높고, 전 세계적으로 매년 백만 명이 새로 발병하고 60만 명이 사망하는 암이다1-3). | |
| 간세포암종의 주요 발생 원인은? | 동아시아, 남동아시아 (10만 명당 남자 20명 이상, 여자 10명 이상) 및 아프리카(10만 명당 남자 15-20명, 여자 8-19명)는 간세포암종 발생율이 높은 지역이고, 미국, Australia, 서북 유럽은 낮은 지역(10만 명당 남자 10명, 여자 3명)이다. B형, C형간염바이러스 간염이 주요 발생 원인이다4). | |
| 간세포암종은 어떤성별에서 더 잘 발생하는가? | 간세포암종(hepatocellular carcinoma)은 간에서 발생하는 암의 80-90%를 차지하는 암이고, 전세계적으로 광범위하게 퍼져 있어서 암 발병율 5위(남성 5위, 여성 7위), 암으로 인한 사망원인으로는 3위를 차지하는 암이다. 간세포암종 (hepatocellular carcinoma)의 남녀 발생 비율은 4:1로 남자가 높고, 전 세계적으로 매년 백만 명이 새로 발병하고 60만 명이 사망하는 암이다1-3). 동아시아, 남동아시아 (10만 명당 남자 20명 이상, 여자 10명 이상) 및 아프리카(10만 명당 남자 15-20명, 여자 8-19명)는 간세포암종 발생율이 높은 지역이고, 미국, Australia, 서북 유럽은 낮은 지역(10만 명당 남자 10명, 여자 3명)이다. |
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-76, 2007
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917, 2010
Center MM, Jemal A. International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev 20:2362-2368, 2011
Bosetti C, Turati F, Vecchia CL. Hepatocellular carcinoma epidemiology. Best Practice & Research Clinical Gastroenterology 28(5): 753-770, 2014
보건복지부 중앙암등록본부. 국가암등록사업 연례 보고서(2012년 암등록통계). 2014
통계청. 2013년 사망 및 사망원인 통계 온라인 간행물, 2014
Lim YS, Shin DH, Kim SH, Korea Central Cancer Registry, Hwang JS. Characteristics and Survival of Korean Patients with Hepatocellular Carcinoma: A Nationwide Random Sample Study. Korean J Liver cancer 14(2):97-107, 2014
박중원. 국가간암조기검진사업. 대한간학회지 8(suppl 3):s16-s19, 2002
？建國, 姚樹坤. 中醫對原發性肝癌的辨證硏究及治療. 中西醫結合肝病雜誌 20(3): 189-191, 2010
林洪生. 惡性腫瘤中醫診療指南. pp371-399, 北京, 人民衛生出版社, 2014
Song P, Tobe RG, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W. The management of hepatocellular carcinoma around the world: a comparison of guideline 2001 to 2011. Liver International 32(7) :1053-1063, 2012
대한간암학회, 국립암센터. 2014 간세포암종 진료 가이드라인(온라인 간행물). p. 1-94, 서울, 2014
Guyatt Gh, Oxman AD, Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924-6, 2008
馮利. 簡明中西醫結合腫瘤病學. p199-213, 北京, 科學技術文獻出版社, 2008
Zhou B. Research on disease, syndrome and symptom of liver cancer in ancient TCM literature. chinese archives of traditional chinese medicine 29(12):2714-15, 2011
Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130:417-422, 2004
Kim JW. National cancer screening program for Hepatocelluar carcinoma. Korean J Med 84(5)670-671, 2013
Kudo M, Izumi N, Kukudo N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M. Management of hepatocellular carcinoma in Japan: Consensu-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 Updated version. Dig Dis 29:339-364, 2011
Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34:570-575, 2001
Chen DS, Sung JL, Sheu JC, Lai MY, How SW, Hsu HC, Lee CS, Wei TC. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 86:1404-1409, 1984
Kudo M, Okanoue T. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 72 Suppl 1:2-15, 2007
Wong GL, Chan HL, Tse YK, Chan HY, Tse CH, Lo AO, Wong VW. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology 59 (3): 986-95, 2014
Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, Duca P. Accuracy of Ultrasonography, Spiral CT, Magnetic Resonance, and Alpha-Fetoprotein in Diagnosing Hepatocellular Carcinoma: A Systematic Review. American Journal of Gastroenterology 101:513-523, 2006
Matsui O. Detection and characterization of hepatocellular carcinoma by imaging. Clin Gastroenterol Hepatol 3:S136-140, 2005
Piscaglia F, Bolondi L. Recent advances in the diagnosis of hepatocellular carcinoma. Hepatol Res 37 Suppl 2:S178-192, 2007
Jain D. Diagnosis of hepatocellular carcinoma: fine needle aspiration cytology or needle core biopsy. J Clin Gastroenterol 35:S101-108, 2002
Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Seminars Liver Dis 30(1):17-25, 2010
Choi JI. Staging of Hepatocellular Carcinoma. korean J of liver cancer study group. 11(1):26-32, 2011
Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, Hokotate H, Inoue H, Baba Y, Imamura Y, Aikou T. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 24(4):395-403, 2002
Forner A, Reig M, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 30:61-74, 2010
鄭？萸. 中藥新藥臨床硏究指導原則(試行). p.208-216, 北京, 中國醫藥科技出版社, 2002
전국한의과대학간계내과학교수. 간계내과학. p.357-373, 서울, 도서출판 나도, 2013
沈旭波, 侯鳳剛, 劉慶, 嶽小？, 顧偉, 鄧哲偉, 王喜. 原發性肝癌1368例中醫單 證出現狀況文獻分析, 中醫藥學刊 22(1):69-70, 2004
陳喆, 侯風剛, 孫克興. 肝癌中醫證型的 文獻分析. 安徽中醫學院學報, 21(2):25-26, 2002
侯鳳剛, ？昌全, 沈旭波, 劉慶, 嶽小？, 顧偉, 鄧哲偉, 王喜, 賀佳. 原發性肝癌中醫證型分布文獻簡析. 中醫雜志 45(11):876-77, 2004
司富春, 嶽靜宇, 劉紫陽. 近30 年臨床原發性肝癌中醫證型和用藥規律分析. 世界中西醫結合雜志 6(1):8-10, 2011
鍾毅, 徐凱, 周紅. 肝癌證候初步？究. 中醫？究 13(5):7-9, 2000
侯鳳剛, ？昌全, 趙鋼, 賀憲民. 原發性肝癌中醫基本證候臨床分布狀況調？分析. 上海中醫藥雜志 39(2):22-23, 2005
方肇勤, 李永健, 唐辰龍, 馬駿, 管冬元, 陳德溯. 2060 例原發性肝癌患者證候特點分析. 中醫雜志 5(1):53-54, 2004
燕忠生, 魏千程, 張慧淵, 孟慶常, 丁輝, ？向勇. 原發性肝癌中醫證型臨床特點與預後關系？究. 實用中醫內科雜志, 20(4):411-12, 2006
楊小兵, 龍順欽, 吳萬垠, 鄧宏, 潘宗奇, 河文峰, 周宇姝, 廖桂雅, 歐陽育樹, 李秋萍, 黃？, 胡學軍, 肖舒靜, 蔡？芝. 原發性肝癌中醫證型分布及生存期差異？究. 中國中西醫結合雜志 33(7):911-914, 2013
鬱仁存, 王笑民. 21世紀中西醫結合腫瘤？究前瞻. 中醫雜誌 42(1)50-52, 2001
Wu P, Dugoua JJ, Eyawo O, Mills EJ. Traditional Chinese medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res 28:112-124, 2009
郭麗詩, 楊蒡, 田雪飛. 中西醫結合原發性肝癌臨床隨機對照硏究的系統評價與Meta分析, 湖南中醫雜誌, 30(7):155-157, 2014
Capussotti L, Muratore A, Massucco P, Ferrero A, Polastri R, Bouzari H. Major liver resections for hepatocellular carcinoma on cirrhosis: early and long-term outcomes. Liver Transpl 10:S64-68, 2004
Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, Wong J. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 234:63-70, 2001
김재홍, 최동욱, 김상범. 대상성 간경변증을 동반한 간세포암에서 대량 간 절제술의 안전성과 장기 성적. 대한외과학회지, 70:444-450, 2006
Huang J, Zhang Y, Peng Z, Gao H, Xu L, Jiao LR, Chen M. A modified TNM-7 staging system to better predict the survival in patients with hepatocellular carcinoma after hepatectomy. J Cancer Res Clin Oncol 139:1709-1719, 2013
Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi E, Makuuchi M. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 257 (5):929-37, 2013
Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 238:703-710, 2003
Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649, 1973
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649-55, 1982
Lee KW. Gobal Discrepancy of Practical Guidelines for Management of Hepatocellular Carcinoma-Resection and Transplanation. Korean J liver study group 11(1):18-22, 2011
Llovet JM, Fuster J, Bruix J. Intention-totreat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434-1440, 1999
Kim DY, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, Lee KS, Chon CY, Han KH. PIVKA-II Is a Useful Tumor Marker for Recurrent Hepatocellular Carcinoma after Surgical Resection. Oncology 72 Suppl 1:52-57, 2007
張院輝, 覃曉, 徐靜, 孫振, ？慶波, 嶽小？, 翟笑楓. 58例肝癌患者手術前後中醫複合證證候特點初步？究. 中西醫結合肝病雜志 22(2):75-80, 2012
傅鳳霞, 張正芳, 王琦. 原發性肝癌手術後辨證治療60例. 南京中醫藥大學學報 13(5):314-315, 1997
陳子瑤, 梁健, 鄧？. 中西醫結合預防原發性肝癌術後複發作用的系統評價. 中國中西醫結合雜志 34(6):671-675, 2014
沈先東, 胡順金, 任克軍, 吳俊. 八珍湯治療腫瘤相關性貧血療效觀察. 中醫藥臨床雜志 22(5):401-403, 2010
李濱, 齊鳳琴, 李燕敏, 劉石磊. 補中益氣湯抗腫瘤作用的實驗？究. 中醫藥學報 34(1): 22-23, 2006
曹娟, 黃宇？. 當歸補血湯治療癌性貧血 的實驗？究. 江西中醫學院學報 5(6):69-71, 2013
周利. 大黃？蟲丸聯合吉西他濱及奧沙利？方案治療原發性肝癌臨床觀察. 新中醫 46(2): 161-163, 2014
王丹, 艾華. 鱉甲煎丸化裁對肝癌22荷瘤小鼠抗腫瘤作用的實驗？究. 中華中醫藥學刊 25(3):582-584, 2007
Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J. Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg 221:291-298, 1995
Matsui O, Kadoya M, Yoshikawa J, Gabata T, Takashima T, Demachi H. Subsegmental transcatheter arterial embolization for small hepatocellular carcinomas: local therapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 33 Suppl:S84-88, 1994
Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, Matsuyama Y, Nakanuma Y, Kojiro M, Makuuchi M, Yamaoka Y. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461-469, 2006
Yoo SH, Bae SH. Complications Associated with Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma. Korean J of liver cancer study group, 11(2):144-148, 2011
Song MJ. Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma. Korean J liver study group 12(2):88-92, 2012
Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R. Prospective randomized study of doxorubicineluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. CardioVascular & Interventional Radiology 33(1):41-52, 2010
Yun HJ, Cho SB, Chung HH. Radioembolization of unresectable hepatocellular carcinoma. Korean J of Liver cancer study group 10(1): 29-34, 2010
Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, Tumino E, Ginanni B, Federici G, Cioni R, Metrangolo S, Bertoni M, Bresci G, Parisi G, Altomare E, Capria A, Bartolozzi C. Conventional versus doxorubicin-eluting bead transarterial chemoemboli zation for hepatocellular carcinoma. J Vasc Interv Radiol 22(11):1545-52, 2011
李？？, ？昌全. 中藥緩解原發性肝癌患者經動脈栓塞化療術後副作用的系統綜述 和meta分析. 中西醫結合學報 10(12):1341-1362, 2012
蔣樹龍, 劉瑞, 花寶金. 中醫藥聯合TACE治療原發性肝癌的系統評價. 遼寧中醫雜志 40(12):2406-2409, 2013
李禹廷, 劉楊, 高文？, 林一帆. 中藥聯合肝動脈栓塞化療治療原發性肝癌有效率Meta分析. 創傷與急危重病醫學 2(6): 341-343, 2014
孟茂斌, 崔堯麗, 官詠松, ？斌. 中藥配合肝動脈塞栓化療治療原發性肝癌隨機對照試驗的Meta分析. 中國循證醫學雜誌 8(1):21-31, 2008
郭尹玲, 鍾森, 扈曉宇, 塗翔. 扶正祛邪法聯合TACE 對中？期肝癌患者生存質量影響的系統評價. 中西醫結合？究 2(3): 116-121, 2010
Thomas MB. Systemic therapy for hepatocellular carcinoma. Cancer Journal 14(2):123-7, 2008
Johnson PJ. Is there a role for systemic therapy in hepatocellular carcinoma, and if so, can we assess response?. Educational book, American Society of Clinical Oncology 2002
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 359(4):378-90, 2008
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncology 10(1): 25-34, 2009
Shu X, McCulloch M, Xiao H, Broffman M, Gao J. Chinese herbal medicine and chemotherapy in the treatment of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Integrative Cancer Therapies 4(3):219-29, 2005
王雄文, 陳日輝, 索拉非尼配合辨證中藥湯劑治療？期原發性肝癌18例臨床觀察. 藥物與臨床 35(5):48-49, 2008
索拉非尼聯合華蟾素片治療中？期原發性肝癌的臨床療效觀察. 中國癌症雜志 22(11):856- 859, 2012
賈瑞明, 宋俊生. 旋覆代？湯及其加減方預防腫瘤化療後惡心嘔吐臨床隨機對照 試驗的Meta分析, 吉林中醫藥 30(3):218-259, 2010
賈淑麗. 橘皮竹茹湯治療腫瘤化療的消化反應58例療效觀察. Clinical Journal of Chinese Medicine 3(13):46-47, 2011
張弦. 八珍湯治療惡性腫瘤放, 化療後骨髓抑制30例臨床觀察. 湖南中醫藥 29(4):51-53, 2013
李寶鴻, 廉南. 加味當歸補血湯對腫瘤患者放化療增效減毒作用的臨床觀察 附:392例病例報告. 成都中醫藥大學學報 28(2):7-9, 2005
王一安. 十全大補湯加減防治化療毒副反應70例臨床觀察. 浙江中醫雜志 46(8):576, 2011
夏淸山. 六味地黃丸在化療中增效減毒作用的臨床觀察. 湖北中醫雜誌 27(11):14-15, 2005
王慶倫, 鮑廷鋒, 許軍. ？瘟敗毒？的藥理作用與臨床應用？況. 江西中醫學院學報 7(4): 183-4, 1995
宋金凱. 參？白術散合四神丸加減治療慢性腹瀉80例. 內蒙古中醫藥 25(6):7, 2006
Jeong TY, Park BK, Cho JH, Son CG. Clinical Analysis of 312 Patients with Hepatobiliary Cancer in Oriental Hospital. Korean J Orient Med 30(5):163-173, 2009
Cho JH, Yoo HS, Lee YW, Son CK, Cho CK.Clinical study in 320 cases for cancer patients on the effect Hangamdan. Thesis Collection of Daejeon University, Institute of korean medicine. 12(2):157-75, 2004
Wang JH, Son JY, Shin JW, Son CK. Hepatoprotective effect of CGX via antioxidative properties in acute mice model. Korean J Orient Int Med. 25:74-81, 2008
Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106:1653-1663, 2006
Kim TH, Kim DY, Park JW, Kim SH, Choi JI, Kim HB, Lee WJ, Park SJ, Hong EK, Kim CM, Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 67(1):225-31, 2007
Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, Zhang RM. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 92(2):184-194, 2009
史玉樹. 腫瘤放療反應的中醫中藥治療. 中國衛生？業 27:175, 2012
陳乃傑, 金源, 劉燕珠, 陳雲鶯. 中醫辨證配合放射治療原發性肝癌的臨床觀察. 浙江中西醫結合雜志 7(3):145-46, 1997
康慶偉, 閻姝. 茵陳蒿湯的藥理作用及臨床應用進展 中國中西醫結合外科雜志19(4): 474-75, 2013
張正升, 彭代銀. 桃紅四物湯臨床應用？究進展. 安徽醫藥 15(5):529-531, 2011
Hong SH, Roh SY, Kim SY, Shin SW, Kim CS, Choi JH, Kim SY, Yim CY, Sohn CH, Song HS, Hong YS. Change in cancer pain management in Korea between 2001 and 2006: results of two nationwide surveys. J Pain Symptom Manage 41(1): 93-103, 2011
Kim JY, Jang WY, Hur MH, Lee KK, Do YR, Park KU, Hong YS, Song HS. Prevalence and management of pain by different age groups of Korean cancer patients. Am J Hosp Palliat Care] 30(4):393-398, 2013
보건복지부. 암성통증관리지침 권고안(제5판). 서울, 보건복지부, 2012
National Comprehensive Cancer Network. NCCN clinical practive guideline in oncology. adult cancer pain. Vol. 1. Fort Washington: National Comprehensive Cancer Network, 2013
杜業勤, 王慶全, 哈木拉提, 吾甫爾. 中藥內服方治療癌性疼痛用藥規律分析. 遼寧中醫雜志 39(7):1330-1332, 2012
張雲燕, 唐穎慧, 彭彩鈺, 鍾森肝癌疼痛的中醫外治？況. 四川中醫 32(2)189-191, 2014
王科, 張穎. 肝癌疼痛的中醫外治？況及思考. 中醫中藥 10(15):138-143, 2013
賈文睿, 侯中偉, ？明河. 針灸療法防治原發性肝癌的？究進展. 針灸臨床雜志 30(2):71-74, 2014
孫其喆, 袁梅. 針灸聯合穴位注射治療肝癌癌痛的系統評價. 大家健康 7(6):184-186, 2013
吳毅軍. 針灸聯合三階藥物療法對原發性肝癌疼痛？痛作用的療效觀察. 湖北中醫藥大學學報 17(1):87-89, 2015
彭輝, 張志芳. 蜂針聯合三階梯止痛療法治療癌痛的臨床觀察. 湖南中醫藥大學學報 30(9):222-225, 2010
葛來安, 彭莉莉, 楊保東. 蜂針聯合中藥治療？期肝癌的臨床體會. 江西中醫藥 40(11): 36-37, 2009
周傑, 梁宜, 陳勤, 方劍喬. 耳針治療癌痛隨機對照？究的Meta分析. 中華中醫藥學刊 32(10):2326-2330, 2014
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 47:207-214, 1981
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216, 2000
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verwejj J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228-247, 2009
Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52-60, 2010
Kim SY. Response Evaluation Assessment in HCC: Modified RECIST. Korean J liver cancer study group. 11(2):111-115, 2011
Choi JI. Treatment Response Evaluation of Hepatocellular Carcinoma. Korean J liver cancer study group. 12(1):16-22, 2012
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.